Lotus Pharmaceutical Co Ltd - Asset Resilience Ratio
Lotus Pharmaceutical Co Ltd (1795) has an Asset Resilience Ratio of 0.49% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Lotus Pharmaceutical Co Ltd (1795) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2022)
This chart shows how Lotus Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 1795 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Lotus Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 1795 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$169.90 Million | 0.49% |
| Total Liquid Assets | NT$169.90 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Lotus Pharmaceutical Co Ltd maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lotus Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lotus Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Lotus Pharmaceutical Co Ltd (2009–2022)
The table below shows the annual Asset Resilience Ratio data for Lotus Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.04% | NT$-10.91 Million ≈ $-343.82K |
NT$29.53 Billion ≈ $930.23 Million |
-0.20pp |
| 2016-12-31 | 0.17% | NT$25.35 Million ≈ $798.76K |
NT$15.24 Billion ≈ $480.27 Million |
-0.16pp |
| 2015-12-31 | 0.32% | NT$49.99 Million ≈ $1.58 Million |
NT$15.50 Billion ≈ $488.40 Million |
-0.13pp |
| 2014-12-31 | 0.46% | NT$74.16 Million ≈ $2.34 Million |
NT$16.27 Billion ≈ $512.60 Million |
-3.88pp |
| 2013-12-31 | 4.33% | NT$86.70 Million ≈ $2.73 Million |
NT$2.00 Billion ≈ $63.03 Million |
-0.33pp |
| 2012-12-31 | 4.66% | NT$50.61 Million ≈ $1.59 Million |
NT$1.09 Billion ≈ $34.19 Million |
-1.29pp |
| 2011-12-31 | 5.95% | NT$66.70 Million ≈ $2.10 Million |
NT$1.12 Billion ≈ $35.31 Million |
+5.67pp |
| 2009-12-31 | 0.28% | NT$2.00 Million ≈ $63.01K |
NT$706.92 Million ≈ $22.27 Million |
-- |
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more